Recursion Pharmaceuticals
RXRX
319 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 115 increasing their positions, 62 reducing their positions, and 35 closing their positions.
242% more capital inflows, than outflows
Capital inflows: $375M | Capital outflows: $110M
94% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 35
85% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 62
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
18% more funds holding
Funds holding: 270 → 319 (+49)
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
14.77% less ownership
Funds ownership: 94.19% → 79.42% (-15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SoftBank Group
Tokyo,
Japan
|
+$98.6M |
| 2 |
Novo Holdings A/S
Hellerup,
Denmark
|
+$68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.5M |
| 4 |
BlackRock
New York
|
+$18.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
-$51.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.68M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$6.42M |
| 4 |
Nikko Asset Management Americas
New York
|
-$5.29M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$5.29M |
RXRX Hedge Fund Activity: Q4 2024 in Review
319 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2024, worth a combined $2.06B — up 18% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new RXRX positions and 35 closed out — a net gain of 33 holders — while 115 added to existing stakes and 62 trimmed.
The largest buyer was SoftBank Group, opening a new position worth an estimated $98.6M. The largest seller was RA Capital Management, cutting an estimated $51.5M.
- 319 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2024, up from 270 in Q3 2024.
- Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
- 68 funds opened new Recursion Pharmaceuticals positions in Q4 2024 and 35 closed out, a net change of +33 holders.
- The largest Recursion Pharmaceuticals buyer in Q4 2024 was SoftBank Group, an estimated $98.6M added.
- The largest Recursion Pharmaceuticals seller in Q4 2024 was RA Capital Management, an estimated $51.5M sold.
Based on aggregated 13F filings for Q4 2024.